NCT02006498View on ClinicalTrials.gov

Silymarin for the Treatment of Non-Alcoholic Fatty Liver Disease (NAFLD)

PHASE2CompletedINTERVENTIONAL
Enrollment

99

Participants

Timeline

Start Date

June 30, 2012

Primary Completion Date

December 31, 2015

Study Completion Date

December 31, 2015

Conditions
Non-alcoholic Fatty Liver Disease
Interventions
DRUG

Sillymarin

Sillymarin is derived from the milk thistle plant, Silybum marianum, a herbal remedy that has been used for centuries for diseases of the liver. It is a complex mixture of 6 major flavonolignans (silybins A and B, isosilybins A and B, silychristin, and silydianin), as well as other minor polyphenolic compounds.

DRUG

Placebo

Placebo capsule with same appearances as study drug

Trial Locations (1)

59100

University Malaya Medical Centre, Kuala Lumpur

All Listed Sponsors
collaborator

Rottapharm

INDUSTRY

lead

University of Malaya

OTHER

NCT02006498 - Silymarin for the Treatment of Non-Alcoholic Fatty Liver Disease (NAFLD) | Biotech Hunter | Biotech Hunter